Association between Clinicopathological Profile and Recurrence of Invasive Breast Carcinoma in Anatomical Pathology FKUI/RSCM

Abstract

ABSTRACT
Background
Breast cancer is the most common malignancy and the leading cause of death in women. Invasive breast carcinoma is a breast
malignancy originating from the glandular epithelium of the breast. Approximately 40% of invasive breast carcinomas had recur.
There are several factors that influence the occurrence of recurrence, such as age, tumor size, lymphovascular invasion, incision
margins, hormonal status and therapy. This study aims to determine the clinicopathological profile associated with recurrence 5
years after therapy for invasive breast carcinoma.
Methods
This study is a retrospective study with data collection carried out through the archives of the Department of Anatomical Pathology,
Faculty of Medicine, University of Indonesia, Dr. Cipto Mangunkusumo General Hospital within a period of 2 years (2014-2015). The
clinicopathological data was searched for up to 5 years of therapy.
Results
From the 54 cases of invasive breast carcinoma in this study, all were women with mean age 48.3 years. A total of 18 cases
(33.3%) experienced recurrence, especially in patients aged ≤50 years, tumor mass size more than 2 cm and luminal B molecular
type. Tumor margin is difficult to evaluate because many review cases do not submit the tumor margin section. Therapy received by
patients was in accordance with standard procedures’ hospital, both neoadjuvant and adjuvant chemotherapy. From the statistical
analysis, there was no significant relation between all profiles that studied with recurrence. It is because the comparison of number
of recurrent and non-recurrent cases is not equal.
Conclusion
One third of advanced invasive breast carcinomas treated with neoadjuvant and showing a partial response have recurrence,
whereas no complete response has recurrence. Tumor size, histologic grade, molecular type and adherence to routine follow-up
treatment influenced the recurrence within 5 years of treatment.